Synergistic Magnesium Composition for Vascular Calcification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vascular calcification, particularly in patients with cardiovascular diseases and renal vascular disease, are limited by the poor bioavailability and side effects of conventional magnesium salts, and the need for a synergistic approach to inhibit calcification effectively.
Innovation Solution
A synergistic composition combining magnesium 2-acetylamino ethane sulfonic acid and 2-methyl-4-aminomethyl-5-hydroxymethyl-3-pyridinol or its salts, which enhances magnesium bioavailability and inhibits advanced glycation end product signaling, thereby reducing vascular calcification without side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional magnesium salts are used to treat vascular calcification, then magnesium supplementation is provided, but bioavailability is poor and side effects occur
Solution Approach 1:
The patent uses magnesium 2-acetylamino ethane sulfonic acid, a chelated magnesium compound, which combines magnesium with an amino acid derivative to improve bioavailability and reduce side effects. This composite approach allows better absorption while maintaining therapeutic effectiveness in inhibiting vascular calcification.
Solution Approach 2:
The patent changes the chemical form of magnesium from conventional salts to a chelated complex with 2-acetylamino ethane sulfonic acid. This parameter change in chemical structure improves solubility and bioavailability, thereby reducing gastrointestinal side effects while enhancing therapeutic action.
2Reliability
If a single agent is used to inhibit vascular calcification, then treatment is simple, but efficacy is insufficient
Solution Approach 1:
The patent combines magnesium 2-acetylamino ethane sulfonic acid with 2-methyl-4-aminomethyl-5-hydroxymethyl-3-pyridinol in a single composition. This merging of two active agents with different mechanisms of action enhances overall efficacy while maintaining a simple single-dose administration regimen.
Solution Approach 2:
The synergistic composition performs multiple functions: magnesium 2-acetylamino ethane sulfonic acid inhibits calcium phosphate deposition, while 2-methyl-4-aminomethyl-5-hydroxymethyl-3-pyridinol inhibits advanced glycation end product signaling. This multi-functional approach increases efficacy without requiring multiple separate treatments.
Data Source
AI summary
The invention disclosed herein relates to synergistic bioactive compositions for inhibiting vascular calcification. Particularly, the present invention relates to exogenous blend of magnesium 2-acetylamino ethane sulfonic acid and 2-methyl-4-aminomethyl-5-hydroxymethyl-3-pyridinol and salts thereof which are present in the weight ratio of 1:0.002 to 1:1.8 along with pharmaceutically acceptable excipients. More particularly, the synergistic composition is useful for treating cardiovascular diseases and renal vascular diseases.